Spots Global Cancer Trial Database for A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Official Title: Treatment With SGN-35 in Patients With CD30-positive Hematologic Malignancies Who Have Previously Participated in an SGN-35 Study
Study ID: NCT00947856
Interventions
Study Description
Brief Summary: This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
Detailed Description: This is a multicenter, open-label study to evaluate single-agent brentuximab vedotin (SGN-35) treatment in patients who previously participated in a brentuximab vedotin study, including Studies SGN35-005 (NCT01100502), SGN35-007 (NCT01026233), and SGN35-008 (NCT01026415). Patients treated on this study (SGN35-006) could re-enroll on study if eligible. The study consisted of 2 arms, as follows: * Retreatment arm: Patients with CD30-positive hematologic malignancies who experienced a complete remission (CR) or partial remission (PR) with previous brentuximab vedotin treatment on a clinical study and subsequently experienced disease progression or relapse. The purpose of this arm was to assess safety and efficacy of retreatment with brentuximab vedotin. * Extension treatment arm: Patients with either CD30-positive hematologic or nonhematologic malignancies who completed treatment in a prior brentuximab vedotin study without unacceptable toxicity and experienced clinical benefit as assessed by the investigator. The purpose of this arm was to enable patients who participated in certain prior brentuximab vedotin trials to receive extension treatment and to assess patient safety and survival in the extension treatment setting.
Eligibility
Minimum Age: 6 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
Stanford Cancer Center, Stanford, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
University of Miami Miller School of Medicine / Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Loyola University Medical Center - Cardinal Bernadin Cancer Center, Maywood, Illinois, United States
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
Washington University School of Medicine, St. Louis, Missouri, United States
The John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
NYU Clinical Cancer Center, New York, New York, United States
Columbia University Medical Center, New York, New York, United States
Nationwide Children's Hospital, Columbus, Ohio, United States
Charles A. Sammons Cancer Center, Dallas, Texas, United States
MD Anderson Cancer Center /The University of Texas, Houston, Texas, United States
Seattle Cancer Care Alliance / University of Washington Medical Center, Seattle, Washington, United States
Hopital Saint-Louis/Service d'Hematologie, Paris, Cedex 10, France
Contact Details
Name: Laurie Grove, PA-C
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
